SCHEMBL13412909

SCHEMBL13412909

O=C(O)Cc1ccc(OC2CCCC2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRA P10827 1/20 0.55
THRB P10828 1/20 0.55
ALDH1A1 P00352 2/20 0.53
TSHR P16473 1/20 0.53
FFAR1 O14842 1/20 0.52
EPHX2 P34913 1/20 0.52
PARP10 Q53GL7 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.47
FAAH O00519 1/20 0.47
ACACB O00763 2/20 0.47
FFAR4 Q5NUL3 2/20 0.46
NAAA Q02083 1/20 0.46
ALOX12 P18054 1/20 0.46
RXRA P19793 1/20 0.46
RXRB P28702 1/20 0.46
RXRG P48443 1/20 0.46
HRH1 P35367 1/20 0.46
CCR3 P51677 1/20 0.46
KCNH2 Q12809 1/20 0.46
CA2 P00918 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2347990 0.98 THRA (0.57) THRATHRBALDH1A1TSHRFFAR1
SCHEMBL17610705 0.97 PARP10 (0.56) THRATHRBALDH1A1TSHRFFAR1
SCHEMBL12985424 0.93 EPHX2 (0.54) THRATHRBALDH1A1TSHRFFAR1
SCHEMBL5690387 0.85 HRH1 (0.63) EPHX2HRH1CCR3KCNH2
SCHEMBL10839780 0.83 ACACB (0.51) ALDH1A1TSHRFFAR1EPHX2PARP10
SCHEMBL3064272 0.83 THRA (0.57) THRATHRBFFAR1EPHX2FFAR4
Hydrochloric Acid SCHEMBL5690396 0.83 HRH1 (0.60) EPHX2HRH1CCR3KCNH2
SCHEMBL5931431 0.83 EPHX2 (0.62) EPHX2FFAR4HRH1CCR3KCNH2
SCHEMBL3272606 0.82 HRH3 (0.57) EPHX2
SCHEMBL2348567 0.82 ALDH1A1 (0.49) ALDH1A1TSHRFFAR1EPHX2PARP10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025151884-A1 USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE PARSONS C LOWELL (US) 2025-07-17 WO claimed
US-20170189443-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) 2017-07-06 US claimed
EP-3110427-A1 COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE Urigen Pharmaceuticals, Inc. (US) 2017-01-04 EP claimed
WO-2015127416-A1 COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE URIGEN PHARMACEUTICALS, INC. (US) 2015-08-27 WO claimed
WO-2025151884-A1 USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE PARSONS C LOWELL (US) 2025-07-17 WO disclosed
CN-105218532-B Benzotriazole compound, preparation method and its medical usage 华东师范大学 2018-05-15 CN disclosed
US-20170189443-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) 2017-07-06 US disclosed
EP-3110427-A1 COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE Urigen Pharmaceuticals, Inc. (US) 2017-01-04 EP disclosed
EP-2129218-B1 COMPOUNDS HAVING A CYCLIC MOIETY AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS EMISPHERE TECH INC (US) 2016-10-19 EP disclosed
WO-2015127416-A1 COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE URIGEN PHARMACEUTICALS, INC. (US) 2015-08-27 WO disclosed
US-8383852-B2 Compounds having a cyclic moiety and compositions for delivering active agents EMISPHERE TECHNOLOGIES, INC. (US) 2013-02-26 US disclosed
US-8383852-B2 Compounds having a cyclic moiety and compositions for delivering active agents EMISPHERE TECHNOLOGIES, INC. (US) 2013-02-26 US disclosed
US-20100074861-A1 COMPOUNDS HAVING A CYCLIC MOIETY AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS EMISPHERE TECHNOLOGIES, INC. (US) 2010-03-25 US disclosed
US-20100074861-A1 COMPOUNDS HAVING A CYCLIC MOIETY AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS EMISPHERE TECHNOLOGIES, INC. (US) 2010-03-25 US disclosed
WO-2008101240-A1 COMPOUNDS HAVING A CYCLIC MOIETY AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS EMISPHERE TECHNOLOGIES, INC. (US) 2008-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100074861-A1 COMPOUNDS HAVING A CYCLIC MOIETY AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS PAICS, ABCB4, ALPP THRA 3597/4885THRB 2855/4885ALDH1A1 2421/4885
US-20170189443-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS SI, SLC20A1, SLC20A2 THRA 4819/4885THRB 4719/4885ALDH1A1 3725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.